M
-
F
,
8
am -
6
pm ET

How Alnylam Assist™ Can Help Your Patients

Alnylam Assist™ is committed to helping patients access therapy. Your patient will work with an Alnylam Case Manager to help them have a smooth treatment experience with ONPATTRO® (patisiran) and answer questions they may have along the way.

Alnylam Assist™ Support Overview

Your patient's Start Form has been submitted. Upon receipt of the Start Form, an Alnylam Case Manager will reach out to you and your patient within 2 business days. Your patient's Case Manager can help them with the following:

Alnylam Assist® - Understanding Your Benefits
Benefit Verification

Help determine patient-specific coverage requirements, which include the following:

Initiate a benefit verification for your patient and provide you and your patient with a benefit verification summary

Provide information about patient financial assistance programs for eligible patients,a if necessary

Alnylam Assist® - Treatment Coverage
Education on the prior authorizations, claims, and appeals processes

Explain the requirements and processes for prior authorizations, claims, and appeals, which include the following:

Research the payer requirements as part of the benefit verification process

Discuss the standard process for submitting a prior authorization and reimbursement claims

Investigate reasons for denied or rejected prior authorizations, claims, and/or appeals

Alnylam Assist® - Financial Assistance Options
Financial Assistance

Alnylam offers financial assistance programs for eligible patients. After being prescribed an Alnylam product, your patient can talk to an Alnylam Case Manager to learn more. Below are examples of two Alnylam financial assistance programs.a

Patient Assistance Program (PAP): Provides Alnylam product at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria

Commercial Copay Program: Covers certain out-of-pocket costs for eligible patients with commercial insuranceb

a  Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

b  Patients with Medicare, Medicaid, or other government sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of ONPATTRO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Alnylam Assist® - Disease and Treatment Education
Disease and Treatment Education

Provide information to your patients:

A Patient Starter Kit, including educational materials designed to help patients understand ONPATTRO and Alnylam Assist

Education for your patients from a designated Alnylam Patient Education Liaison (PEL) to help them gain a better understanding of polyneuropathy of hereditary transthyretin-mediated amyloidosis and treatment with ONPATTRO. PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice.

Alnylam Assist® - Facilitation of Product Orders
Ordering product for your patient

a  Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

b  Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of ONPATTRO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Alnylam Field Reimbursement Directors

Alnylam Field Reimbursement Directors (FRDs) are available to provide education about coverage, coding and reimbursement process for ONPATTRO. FRDs will share their knowledge of:

ONPATTRO billing and coding requirements

Chart documentation requirements

Payer requirements

Download Brochures and Guides

Healthcare Professionals

Alnylam Assist™ Support

Services Overview Brochure

Alnylam Assist® Services Overview Brochure for HCPs Thumbnail - for ONPATTRO® (Patisiran)

Download

Patients + Caregivers

Alnylam Assist™ Brochure (PDF)

 

Alnylam Assist® Brochure for Patients Thumbnail - for ONPATTRO®(Patisiran)

Download

Where can I find the necessary forms and documents to enroll patients in Alnylam Assist™?

Alnylam Assist™ provides all the required forms and documents to enroll your patients, as well as downloadable educational resources. View the associated ONPATTRO forms and documents ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›

or

Alnylam Assist® Start Form - To Print And Fax

Print
& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle

IMPORTANT SAFETY INFORMATION

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

INDICATION

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.